Stocktoria
Alkermes plc. ALKS
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 1991-07-16
Alkermes plc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5B | $1.6B | $1.7B | $1.1B | $1.2B | $1.0B | $1.2B | $1.1B | $903.4M | $745.7M |
| R&D expense | $324.0M | $245.3M | $270.8M | $272.7M | $290.9M | $394.6M | $512.8M | $425.4M | $412.9M | $387.1M |
| SG&A expense | $701.5M | $645.2M | $689.8M | $590.8M | $549.6M | $538.8M | $599.4M | $526.4M | $421.6M | $374.1M |
| Operating income | $254.0M | $420.6M | $414.1M | -$6.1M | $97.7M | -$112.4M | -$175.5M | -$99.1M | -$147.9M | -$208.7M |
| Interest expense | — | — | $23.0M | $13.0M | $11.2M | $8.7M | $13.6M | $15.4M | $12.0M | $14.9M |
| Income tax | $49.8M | $71.6M | -$97.6M | $2.0M | $11.3M | $14.3M | -$436,000 | $12.3M | $14.7M | -$5.9M |
| Net income | $241.7M | $367.1M | $355.8M | -$158.3M | -$48.2M | -$110.9M | -$196.6M | -$139.3M | -$157.9M | -$208.4M |
| EPS (diluted) | $1.43 | $2.17 | $2.10 | $-0.97 | $-0.29 | $-0.70 | — | — | — | — |
| Operating cash flow | $520.8M | $439.1M | $401.4M | $21.0M | $101.7M | $82.8M | $72.1M | $99.3M | $19.2M | -$63.8M |
| Free cash flow | $480.3M | $405.6M | $353.3M | -$17.2M | $73.7M | $40.6M | -$18.9M | $29.9M | -$32.1M | -$107.5M |
| Cash & equivalents | $388.6M | $291.1M | $457.5M | $292.5M | $337.5M | $273.0M | $203.8M | $266.8M | $191.3M | $186.4M |
| Inventory | $196.6M | $182.9M | $186.4M | $181.4M | $150.3M | $125.7M | $101.8M | $90.2M | $93.3M | $63.0M |
| Total assets | $2.5B | $2.1B | $2.1B | $2.0B | $2.0B | $1.9B | $1.8B | $1.8B | $1.8B | $1.7B |
| Total liabilities | $667.7M | $590.6M | $933.5M | $920.2M | $911.9M | $882.7M | $720.0M | $653.7M | $594.4M | $516.9M |
| Shareholders' equity | $1.8B | $1.5B | $1.2B | $1.0B | $1.1B | $1.1B | $1.1B | $1.2B | $1.2B | $1.2B |
Growth · year-over-year · Revenue CAGR 7.9%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -5.2% | -6.4% | +49.6% | -5.3% | +13.0% | -11.3% | +7.0% | +21.1% | +21.1% | +18.7% |
| Net income growth | -34.2% | +3.2% | — | — | — | — | — | — | — | — |
| EPS growth | -34.1% | +3.3% | — | — | — | — | — | — | — | — |
| Free cash flow growth | +18.4% | +14.8% | — | -123.4% | +81.4% | — | -163.2% | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.